2nd Line Relapsed or Metastatic Mucosal HNSCC not NPC

**Treatment**

**No Injectable Lesions**

- **Prior - PD(L)1**
  - **ECOG-ACRIN-EA3202**
    - Phase III/III Chemotherapy + Celecoxib vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head & Neck Cancers
    - PI: Khan
    - Sponsor: ECOG-ACRIN
  - **ENT0100**
    - Phase I Multicenter Open Label First-in-Human ABBV-CLS-579 Alone and in Combination in Locally Advanced or Metastatic Tumors
    - PI: Colevas
    - Sponsor: AbbVie Inc.

- **Max 2 Prior Therapies**
  - **ENT0088**
    - Phase II Magrolimab Combination Therapy in Head and Neck Squamous Cell Carcinoma
    - Safety Run-in 2 / Phase 2 Cohort 3
    - PI: Colevas
    - Sponsor: Gilead Sciences, Inc.

- **Max 4 Prior Therapies in R/M Setting**
  - **ENT0105**
    - Phase III Study of SRF114 in Patients With Advanced Solid Tumors
    - PI: Colevas
    - Sponsor: Surface Oncology, Inc.

**Injectable Lesions**

- **None at This Time**

---

**KEY**

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Link
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold